A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
Status:
Recruiting
Trial end date:
2024-01-12
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to determine: the recommended Phase 2 doses (RP2Ds) of
JNJ-64264681 and JNJ 67856633 when administered together in participants with B cell
non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) (Part A - Dose Escalation);
and the safety of the RP2Ds for this combination in different histologies/participant
populations (Part B - Cohort Expansion).